DK0787008T3 - Thyamosin alfa1 i kombination med en naturlig cytokinblanding til behandling af en cellulær immunmangel - Google Patents

Thyamosin alfa1 i kombination med en naturlig cytokinblanding til behandling af en cellulær immunmangel

Info

Publication number
DK0787008T3
DK0787008T3 DK95940751T DK95940751T DK0787008T3 DK 0787008 T3 DK0787008 T3 DK 0787008T3 DK 95940751 T DK95940751 T DK 95940751T DK 95940751 T DK95940751 T DK 95940751T DK 0787008 T3 DK0787008 T3 DK 0787008T3
Authority
DK
Denmark
Prior art keywords
cellular immune
immune deficiency
thyamosin
alfa1
blend
Prior art date
Application number
DK95940751T
Other languages
Danish (da)
English (en)
Inventor
John W Hadden
Original Assignee
Univ South Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ South Florida filed Critical Univ South Florida
Application granted granted Critical
Publication of DK0787008T3 publication Critical patent/DK0787008T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57581—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Processing Of Meat And Fish (AREA)
  • Medicines Containing Plant Substances (AREA)
DK95940751T 1994-11-17 1995-11-16 Thyamosin alfa1 i kombination med en naturlig cytokinblanding til behandling af en cellulær immunmangel DK0787008T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/341,424 US5632983A (en) 1994-11-17 1994-11-17 Method for treating secondary immunodeficiency
PCT/US1995/015038 WO1996015800A1 (fr) 1994-11-17 1995-11-16 Methode de traitement de l'immunodeficience secondaire

Publications (1)

Publication Number Publication Date
DK0787008T3 true DK0787008T3 (da) 2009-05-11

Family

ID=23337510

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95940751T DK0787008T3 (da) 1994-11-17 1995-11-16 Thyamosin alfa1 i kombination med en naturlig cytokinblanding til behandling af en cellulær immunmangel

Country Status (12)

Country Link
US (1) US5632983A (fr)
EP (2) EP2036569A3 (fr)
JP (3) JP4416839B2 (fr)
AT (1) ATE419860T1 (fr)
AU (1) AU702770B2 (fr)
CA (1) CA2205405C (fr)
DE (1) DE69535904D1 (fr)
DK (1) DK0787008T3 (fr)
ES (1) ES2320280T3 (fr)
MX (1) MX9703627A (fr)
PT (1) PT787008E (fr)
WO (1) WO1996015800A1 (fr)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5674483A (en) * 1995-01-31 1997-10-07 National Jewish Medical And Research Center Treatment for diseases involving inflammation
DE19608280A1 (de) * 1996-02-23 1997-08-28 Strathmann Ag & Co Arzneimittel zur kausalen Therapie von HIV- oder SIV-Infektionen
US6261537B1 (en) 1996-10-28 2001-07-17 Nycomed Imaging As Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors
WO1999020788A1 (fr) 1997-10-17 1999-04-29 University Of South Florida Procede de diagnostic et de surveillance des deficiences immunitaires cellulaires
US6197751B1 (en) * 1997-11-10 2001-03-06 The United States Of America As Represented By The Department Of Health And Human Services Thymosin α1 promotes tissue repair, angiogenesis and cell migration
IT1298487B1 (it) * 1997-12-19 2000-01-10 Sigma Tau Ind Farmaceuti Composizioni farmaceutiche comprendenti pentraxina lunga ptx3 per la terapia di patologie di tipo infettivo, infiammatorio o tumorale,
US6440448B1 (en) * 1998-03-16 2002-08-27 Joseph Intelisano Food supplement/herbal composition for health enhancement
US6348050B1 (en) * 1999-04-30 2002-02-19 Medtronic, Inc. Infusion systems for creating microenvironments in a living body
US7030219B2 (en) 2000-04-28 2006-04-18 Johns Hopkins University B7-DC, Dendritic cell co-stimulatory molecules
US7431920B2 (en) * 2000-07-19 2008-10-07 Pepgen Corporation Method of treating IL-10 deficiency
US20050118138A1 (en) * 2000-07-19 2005-06-02 Chih-Ping Liu Method of treatment using interferon-tau
US20050226845A1 (en) * 2004-03-10 2005-10-13 Chih-Ping Liu Method of treatment using interferon-tau
US20050084478A1 (en) * 2000-10-17 2005-04-21 Chih-Ping Liu Combination therapy using interferon-tau
US20050201981A1 (en) * 2004-03-10 2005-09-15 Chih-Ping Liu Method of optimizing treatment with interferon-tau
US20040247565A1 (en) * 2000-07-19 2004-12-09 Chih-Ping Liu Method of treatment using interferon-tau
US20050118137A1 (en) * 2000-07-19 2005-06-02 Chih-Ping Liu Method of treatment using interferon-tau
AU7577100A (en) 2000-09-11 2002-03-26 Therapro Technologies Inc Thionin as an antineoplastic and immunostimulant
US20070154399A1 (en) * 2000-10-27 2007-07-05 Hadden John W Immunotherapy for immune suppressed patients
US20060194242A1 (en) * 2000-10-27 2006-08-31 Hadden John W Immunotherapy for immune suppressed patients
US20070031372A1 (en) * 2004-08-05 2007-02-08 Hadden John W Vaccine immunotherapy for immune suppressed patients
US7182942B2 (en) 2000-10-27 2007-02-27 Irx Therapeutics, Inc. Vaccine immunotherapy for immune suppressed patients
US20070025958A1 (en) * 2000-10-27 2007-02-01 Hadden John W Vaccine immunotherapy
CA2464228C (fr) 2000-10-27 2017-01-17 Immuno-Rx, Inc. Immunotherapie vaccinale pour patients immunodeprimes
WO2002055547A2 (fr) 2001-01-10 2002-07-18 The Government Of The United States Of America, Asrepresented By The Secretary, Department Of Health And Human Services Sfrp et motifs de peptides interagissant avec sfrp et methodes d'utilisation correspondantes
JP2005510491A (ja) * 2001-10-26 2005-04-21 イミュノ−アールエックス， インコーポレイテッド 免疫抑制を逆転させるための免疫治療
UA78726C2 (en) * 2001-11-01 2007-04-25 Sciclone Pharmaceuticals Inc Pharmaceutical composition of thymosin alpha 1 conjugated with polyethylene glycol, method for production, and method for treatment
UA80957C2 (en) * 2001-11-01 2007-11-26 Sciclone Pharmaceuticals Inc Method of administering a thymosin alpha 1 peptide
BRPI0408892A (pt) * 2003-03-28 2006-04-11 Sciclone Pharmaceuticals Inc uso de timosina alfa 1 para tratar as infecções por arpergillus
US20100311656A1 (en) * 2003-04-23 2010-12-09 Sciclone Pharmaceuticals, Inc. Treatment or prevention of respiratory viral infections with alpha thymosin peptides
US6896879B2 (en) * 2003-07-03 2005-05-24 Cel-Sci Corporation Method of pre-sensitizing cancer prior to treatment with radiation and/or chemotherapy and a novel cytokine mixture
US20060078942A1 (en) * 2004-03-10 2006-04-13 Pepgen Corporation Method of treatment using interferon-tau
US20080025948A1 (en) * 2004-03-10 2008-01-31 Chih-Ping Liu Methods of Treatment Using Interferon-Tau
AU2005269400A1 (en) * 2004-07-30 2006-02-09 Cel-Sci Corporation A method for managing cholesterol with a serum-free and mitogen free cytokine mixture
DK2012816T3 (da) * 2006-05-02 2012-09-03 Sigma Tau Ind Farmaceuti Anvendelse af Thymosin 1, alene eller i kombination med PTX3 eller Ganciclovir, til behandling af Cytomegalovirus infektion.
US8017129B2 (en) 2006-06-15 2011-09-13 SciClone Pharmaceuticals International Ltd Use of thymosin alpha 1 for preparing a medicament for the treatment of stage IV malignant melanoma
US7993660B2 (en) 2007-11-28 2011-08-09 Irx Therapeutics, Inc. Method of increasing immunological effect
ES2545609T3 (es) 2008-08-25 2015-09-14 Amplimmune, Inc. Composiciones de antagonistas de PD-1 y métodos de uso
JP2012500652A (ja) * 2008-08-25 2012-01-12 アンプリミューン、インコーポレーテッド 標的化共刺激ポリペプチドおよび癌を処置するための使用方法
US8066949B2 (en) * 2008-09-26 2011-11-29 Exxonmobil Research & Engineering Company Scrubber for fluid coker unit
EP2427213B1 (fr) * 2009-05-08 2015-04-01 Sciclone Pharmaceuticals, Inc. Peptide de type thymosine alpha pour renforcer l'efficacité des vaccins
JP5797190B2 (ja) 2009-05-15 2015-10-21 アイ アール エックス セーラピューティクス， インコーポレイテッド ワクチン免疫療法
US20110070269A1 (en) * 2009-09-24 2011-03-24 Therapro Technologies, Inc. Lipopolysaccharide isolated from pyrularia tissue and/or pyrularia-associated bacteria and uses thereof
US9333238B2 (en) 2009-12-08 2016-05-10 Irx Therapeutics, Inc. Method of immunotherapy for treament of human papillomavirus infection
CN110101843A (zh) * 2018-02-01 2019-08-09 北京科诺科服生物科技有限公司 一种抗肿瘤蛋白质及其应用
EP4422668A1 (fr) * 2021-10-25 2024-09-04 Ellennbe GmbH Composition pharmaceutique et kit correspondant comprenant une substance immunomodulatrice pour le traitement de maladies
WO2024084038A1 (fr) * 2022-10-20 2024-04-25 Ellennbe Gmbh Technologie de plateforme pour le traitement de maladies inflammatoires, immunologiques et/ou auto-immunologiques

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4079127A (en) 1976-10-28 1978-03-14 Board Of Regents Of The University Of Texas Thymosin alpha 1
US4116951A (en) * 1977-04-22 1978-09-26 Hoffmann-La Roche Inc. [Asn2 ]-thymosin α1 and analogs thereof
US4148788A (en) 1978-01-23 1979-04-10 Hoffmann-La Roche Inc. Synthesis of thymosin α1
DE2919592A1 (de) * 1979-05-15 1981-01-15 Max Planck Gesellschaft Verfahren zur herstellung von thymosin- alpha 1 und derivaten davon
DE3100974A1 (de) * 1980-01-18 1982-01-21 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen Thymosin(alpha)(pfeil abwaerts)1(pfeil abwaerts)-fragmente enthaltende arzneimittel mit immunregulierender wirkung, und thymosin(alpha)(pfeil abwaerts)1(pfeil abwaerts)-fragmente
US4470926A (en) * 1980-01-18 1984-09-11 Max-Planck-Gesellschaft zur F/o/ rderung der Wissenschaften e.V. Medicaments containing thymosin alpha 1 fragments and having an immunostimulant action, and fragments of thymosin alpha 1
US4612365A (en) * 1980-03-25 1986-09-16 Max-Planck-Gesellschaft Zur Foederung Der Wissenschaften Medicaments containing alpha 1-thymosin and having an immuno regulatory action and alpha 1-thymosin fragments
US4293455A (en) 1980-04-07 1981-10-06 Rockefeller University N.sup.α -Desacetylthymosinα1 and process
US4390623A (en) 1980-10-02 1983-06-28 Hooper Trading Company Serum-free and mitogen-free T-cell growth factor and process for making same
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4448879A (en) 1981-03-26 1984-05-15 Hooper Trading Company High yield process for in vitro production of serum-free and mitogen-free interleukin-2
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4504415A (en) 1983-04-04 1985-03-12 Hoffman-La Roche Inc. Synthesis of thymosin α1 and desacetyl thymosin α1
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
FR2546267B1 (fr) 1983-05-19 1985-07-26 Aubry Cie Sa Structure d'enveloppe ou de panneau composite multicouches
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4614731A (en) 1983-09-15 1986-09-30 Hoffmann-La Roche Inc. Peptide having immunopotentiating activity similar to thymosin alpha1
US4659694A (en) * 1983-10-27 1987-04-21 Hoffmann-La Roche Inc. Prothymosin alpha
US4569790A (en) 1984-03-28 1986-02-11 Cetus Corporation Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions
US4716148A (en) * 1984-08-13 1987-12-29 Hoffman-La Roche Inc. Prothymosin alpha
US5093114A (en) * 1985-03-16 1992-03-03 Burroughs Wellcome Co. Treatment of human viral infections
US4935233A (en) * 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
IT1238231B (it) * 1989-12-18 1993-07-12 Consiglio Nazionale Ricerche Impiego di immunomodulanti come agenti sinergici di chemioterapici nella terapia dei tumori
CN1094310A (zh) * 1992-12-15 1994-11-02 托马斯·C·梅里根 人体免疫缺陷性病毒感染用组合式化学疗法

Also Published As

Publication number Publication date
AU702770B2 (en) 1999-03-04
EP2036569A2 (fr) 2009-03-18
EP0787008A1 (fr) 1997-08-06
EP0787008B1 (fr) 2009-01-07
US5632983A (en) 1997-05-27
EP0787008A4 (fr) 1999-02-10
PT787008E (pt) 2009-03-23
AU4240096A (en) 1996-06-17
WO1996015800A1 (fr) 1996-05-30
JPH10509955A (ja) 1998-09-29
ATE419860T1 (de) 2009-01-15
JP4416839B2 (ja) 2010-02-17
JP2006306898A (ja) 2006-11-09
EP2036569A3 (fr) 2009-04-01
CA2205405A1 (fr) 1996-05-30
CA2205405C (fr) 2003-02-04
MX9703627A (es) 1998-07-31
DE69535904D1 (de) 2009-02-26
JP2009029830A (ja) 2009-02-12
ES2320280T3 (es) 2009-05-20

Similar Documents

Publication Publication Date Title
ATE419860T1 (de) Kombination aus thymosin alpha1 und einem natürlichen zytokin-gemisch zur behandlung zellulärer immunschwäche
NO963742D0 (no) Fremgangsmåte til å stimulere hematopoese med hemaglobin
DK0585943T3 (da) Opløselige ligander for CD40
ATE141928T1 (de) Osteoinduktive mittel
DE69317979D1 (de) PEG-Interferon-Konjugate
DK10389A (da) Fremgangsmaade til stimulering af haarvaekst
DE68924162D1 (de) Stressproteine und verwendungen dafür.
MX9805810A (es) Agentes anticoagulantes, utiles en el tratamiento de trombosis.
FI970747A0 (fi) Yhdistelmävalmiste käytettäväksi immunologisissa sairauksissa
ATA152786A (de) Verfahren und turbo-sichter zum streuwindsichten, insbesondere von zement
GR1002802B (el) Καλλυντικες συνθεσεις και συνθεσεις περιποιησεως του δερματος
DK487587A (da) Fluor- og calsiummidler med forsinket frigivelse
DK45787D0 (da) Taphaneventil med stoejreducerende spalter og flige i forud lukkende aabninger
DE69128781D1 (de) Zusammensetzung und methode zur immunstimulierung in säugetieren
DE69213529D1 (de) Nylonzusammensetzung mit erhöhter Hydrolysierbarkeit und Verfahren zur Erhöhung der Hydrolysierbarkeit von Nylon
DK0579488T3 (da) Præparat til behandling af mastitis og matritis
DK1076561T3 (da) Kombinationsterapi til behandlingen af tumorer
ATE155345T1 (de) Gegengift immunsera
TR199801988T2 (xx) Kalp yetmezli�inin endotelin antagonistleri ile tedavisi i�in y�ntem.
TR199800575T1 (en) Kemokin �-8'in k�sa formlar�.
AU6989998A (en) Amino acid compositions and use thereof in clinical nutrition
DK1007085T3 (da) Anvendelse af væksthormon i præparater til behandling af insulin-resistens i hjertet
DK0900085T3 (da) Behandling af overdreven aggression med olanzapin
ES551053A0 (es) Perfeccionamientos en el metodo de tratamiento de simil-cuero y cuero
IL96103A0 (en) Method and composition for treating leg weakness in fowl